SCHEMBL5224150

SCHEMBL5224150

COc1ccc(C(=O)c2cccc(N)c2NC(=O)C2CCN(Cc3c(F)c(F)c(F)c(F)c3F)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.46
ALDH1A1 P00352 1/20 0.45
KDM4E B2RXH2 3/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ACKR3 P25106 3/20 0.43
PRKAB2 O43741 1/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42
PRKAA1 Q13131 1/20 0.42
PRKAG3 Q9UGI9 1/20 0.42
PRKAG2 Q9UGJ0 1/20 0.42
PRKAB1 Q9Y478 1/20 0.42
MAPK1 P28482 1/20 0.41
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.40
BACE1 P56817 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223734 0.88 CHRM4 (0.51) ACHEACKR3PRKAB2PRKAG1PRKAA2
SCHEMBL7243422 0.86 ACKR3 (0.49) ACHEKDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL7244579 0.85 KMT2A (0.47) ACHEALDH1A1KDM4ECYP3A4CYP2C9
SCHEMBL5227303 0.85 CYP2D6 (0.49) ACHEALDH1A1KDM4ECYP3A4CYP2C9
SCHEMBL5224692 0.85 CYP3A4 (0.48) ACHECYP3A4CYP2C9ACKR3PRKAB2
SCHEMBL7246833 0.85 ACKR3 (0.48) ACHEACKR3PRKAB2PRKAG1PRKAA2
SCHEMBL5222681 0.85 CYP3A4 (0.45) ACHEALDH1A1KDM4ECYP3A4CYP2C9
SCHEMBL5225392 0.84 ALDH1A1 (0.50) ACHEALDH1A1KDM4ECYP2C19KMT2A
SCHEMBL5226525 0.84 PRKAB2 (0.52) ACHEKDM4EACKR3PRKAB2PRKAG1
SCHEMBL7249950 0.84 ACKR3 (0.45) ACHEKDM4ECYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 ACHE 999/4885ALDH1A1 835/4885KDM4E 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.